ISSN-3049-2955
Guidelines for Authors
CURRENT PHARMACEUTICAL RESEARCH
Current Pharmaceutical Research (CPR) is an open-access, peer-reviewed journal dedicated to the publication of high-quality, original, and scientifically rigorous research and scholarly contributions across the broad field of pharmaceutical and biomedical sciences. The journal covers a wide range of disciplines, including pharmaceutical sciences, drug discovery and development, drug delivery, pharmaceutics, pharmacology, medicinal chemistry, pharmaceutical biotechnology, nanotechnology, clinical pharmacy, pharmacognosy, pharmaceutical analysis, and related biomedical sciences.
CPR welcomes Original Research Articles, Review Articles, Short Communications, Brief Reports, and other scientifically relevant contributions that provide novel insights, advance current knowledge, and have potential significance for pharmaceutical research, healthcare, and biomedical applications.
1. TYPES OF MANUSCRIPTS
Current Pharmaceutical Research (CPR) considers the following categories of manuscripts for publication.
1.1 ORIGINAL RESEARCH ARTICLES
Original Research Articles should report novel and scientifically rigorous findings from experimental, computational, clinical, formulation, analytical, pharmaceutical, or translational research. The manuscript should clearly describe the research objective, methodology, results, interpretation, and significance of the findings.
The recommended structure for Original Research Articles is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Materials and Methods
(viii) Results
(ix) Discussion
(x) Conclusion
(xi) Acknowledgments
(xii) Author Contributions
(xiii) Funding
(xiv) Conflict of Interest
(xv) Data Availability Statement
(xvi) AI/LLM Declaration, where applicable
(xvii) References
1.2 REVIEW ARTICLES
Review Articles should provide a comprehensive, critical, and up-to-date synthesis of published literature on an important topic within pharmaceutical, biomedical, and related sciences. Review manuscripts should critically evaluate existing evidence, identify emerging developments and research gaps, and provide meaningful scientific perspectives rather than simply summarizing previously published information.
Authors are encouraged to address recent developments, mechanistic insights, translational significance, current challenges, research gaps, and future perspectives relevant to the topic.
The recommended structure for Review Articles is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Main Thematic Sections
(viii) Critical Discussion
(ix) Challenges and Limitations
(x) Future Perspectives
(xi) Conclusion
(xii) Acknowledgments
(xiii) Author Contributions
(xiv) Funding
(xv) Conflict of Interest
(xvi) Data Availability Statement, where applicable
(xvii) AI/LLM Declaration, where applicable
(xviii) References
1.3 SHORT COMMUNICATIONS
Short Communications should present concise but scientifically significant findings that warrant timely dissemination. The manuscript should focus on a specific research finding, observation, methodology, or scientific advancement and provide sufficient information to support the reported conclusions.
The recommended structure for Short Communications is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Materials and Methods
(viii) Results and Discussion
(ix) Conclusion
(x) Acknowledgments, where applicable
(xi) Author Contributions
(xii) Funding
(xiii) Conflict of Interest
(xiv) Data Availability Statement, where applicable
(xv) AI/LLM Declaration, where applicable
(xvi) References
1.4 BRIEF REPORTS
Brief Reports may present preliminary, focused, or technically important findings supported by sufficient scientific evidence. The manuscript should clearly communicate the research objective, methodology, principal findings, and scientific relevance in a concise format.
The recommended structure for Brief Reports is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Materials and Methods
(viii) Results and Discussion
(ix) Conclusion
(x) Acknowledgments, where applicable
(xi) Author Contributions
(xii) Funding
(xiii) Conflict of Interest
(xiv) Data Availability Statement, where applicable
(xv) AI/LLM Declaration, where applicable
(xvi) References
1.5 CASE REPORTS
Case Reports describing clinically significant, unusual, or noteworthy pharmaceutical, pharmacological, medical, or therapeutic observations may be considered for publication. The report should provide sufficient clinical or scientific details, demonstrate relevance to the journal's scope, and address appropriate ethical and confidentiality requirements.
The recommended structure for Case Reports is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Case Presentation
(viii) Investigations and Clinical Findings, where applicable
(ix) Treatment or Intervention, where applicable
(x) Outcome and Follow-up, where applicable
(xi) Discussion
(xii) Conclusion
(xiii) Patient Consent and Ethical Statement, where applicable
(xiv) Acknowledgments, where applicable
(xv) Author Contributions
(xvi) Funding
(xvii) Conflict of Interest
(xviii) Data Availability Statement, where applicable
(xix) AI/LLM Declaration, where applicable
(xx) References
1.6 METHODOLOGY AND TECHNICAL ARTICLES
Methodology and Technical Articles may describe novel or substantially improved analytical, formulation, computational, experimental, pharmaceutical, or biomedical methodologies. Manuscripts should provide adequate methodological details to facilitate reproducibility and should clearly explain the advantages, applications, limitations, and scientific significance of the proposed method or technique.
The recommended structure for Methodology and Technical Articles is as follows:
(i) Title
(ii) Authors and Affiliations
(iii) Corresponding Author
(iv) Abstract
(v) Keywords
(vi) Introduction
(vii) Materials and Methods
(viii) Method Development or Technical Description
(ix) Validation and/or Performance Evaluation
(x) Results and Discussion
(xi) Applications and Limitations
(xii) Conclusion
(xiii) Acknowledgments, where applicable
(xiv) Author Contributions
(xv) Funding
(xvi) Conflict of Interest
(xvii) Data Availability Statement, where applicable
(xviii) AI/LLM Declaration, where applicable
(xix) References
2. GENERAL MANUSCRIPT REQUIREMENTS
Manuscripts should:
(i) Be written in clear and grammatically correct English.
(ii) Contain original and unpublished work.
(iii) Be submitted exclusively to CPR while under consideration.
(iv) Not have been published previously in whole or substantial part.
(v) Follow appropriate ethical standards.
(vi) Provide sufficient methodological information to allow reproducibility.
(vii) Cite relevant and recent literature appropriately.
(viii) Avoid unnecessary duplication of information.
(ix) Clearly distinguish authors' original findings from previously published information.
3. MANUSCRIPT FORMATTING
Authors should prepare manuscripts according to the following formatting requirements:
(i) Font: Times New Roman.
(ii) Font Size: 12 pt.
(iii) Line Spacing: 1.5.
(iv) Text Alignment: Justified.
(v) Page Size: A4.
(vi) Margins: 1 inch on all sides.
(vii) Page Numbering: All pages should be numbered consecutively.
(viii) Units: Standard SI units should be used wherever applicable.
(ix) Abbreviations: Only internationally accepted abbreviations should be used. Abbreviations should be defined at their first appearance in the main text and used consistently thereafter.
(x) Headings and Subheadings: The manuscript should be logically organized using appropriately numbered headings and subheadings.
(xi) Language: Manuscripts should be written in clear, concise, and grammatically correct English.
(xii) File Format: Manuscripts should be submitted in Microsoft Word (.doc or .docx) format.
4. TITLE PAGE
The title page should provide complete and accurate information about the manuscript and all contributing authors. The title should be concise, informative, specific to the study, free from unnecessary abbreviations, and reflective of the major scientific contribution of the manuscript.
The title page should include the following information:
(i) Title of the manuscript.
(ii) Full names of all authors.
(iii) Department, School, Faculty, or other relevant academic unit.
(iv) Institutional or University affiliation.
(v) City, State/Province, and Country.
(vi) Corresponding Author details.
(vii) Full name of the corresponding author.
(viii) Institutional affiliation of the corresponding author.
(ix) Institutional email address of the corresponding author.
(x) ORCID iD, if available.
Authors should carefully verify the spelling, sequence, affiliations, and contact details of all authors before submitting the manuscript. Any changes to author names, order, or affiliations after submission may require approval from all authors and the editorial office.
5. ABSTRACT
The abstract should provide a concise and self-contained summary of the manuscript. It should clearly communicate the purpose, scope, major findings, and significance of the work without requiring reference to the main text.
5.1 ORIGINAL RESEARCH ARTICLES
The abstract should generally contain 150–250 words and should concisely describe the following components:
(i) Background: Briefly describe the scientific context and rationale of the study.
(ii) Objective: Clearly state the primary objective or research question.
(iii) Methods: Summarize the key experimental, computational, clinical, analytical, or other methods used.
(iv) Results: Present the principal findings, including important quantitative results wherever appropriate.
(v) Conclusion: State the major conclusions and scientific significance of the findings.
5.2 REVIEW ARTICLES
The abstract should generally contain 150–250 words and should provide a concise overview of the review, including:
(i) Background and Rationale: Introduce the scientific context and importance of the topic.
(ii) Scope of the Review: Clearly indicate the focus and coverage of the review.
(iii) Major Findings and Themes: Summarize the principal findings, emerging evidence, and important themes discussed.
(iv) Critical Conclusions: Present the major conclusions derived from the available evidence.
(v) Future Implications: Highlight important research gaps, challenges, and potential future directions.
The abstract should be understandable independently of the main manuscript. References, citations, tables, figures, and unexplained abbreviations should generally not be included in the abstract unless their use is considered essential.
6. KEYWORDS
Authors should provide 4–6 keywords immediately after the abstract. Keywords should accurately represent the major concepts, scientific themes, methods, or applications discussed in the manuscript.
Authors should follow the following recommendations:
(i) Keywords should represent the major concepts and scientific focus of the manuscript.
(ii) Keywords should be specific and relevant to the subject of the manuscript.
(iii) Unnecessary duplication of words or phrases already appearing in the title should be avoided where possible.
(iv) Internationally recognized scientific and technical terminology should be used.
(v) Keywords should be separated by semicolons.
Example:
Keywords: Drug delivery; Nanotechnology; Pharmaceutics; Molecular docking; Pharmacokinetics; Drug discovery
7. MAIN MANUSCRIPT
7.1 INTRODUCTION
The Introduction should provide a clear and concise overview of the scientific background and rationale of the study. It should establish the context of the research, explain the significance of the topic, and clearly define the problem or research question being addressed.
Authors should ensure that the Introduction:
(i) Provides relevant and up-to-date scientific background.
(ii) Explains the importance and scientific relevance of the research topic.
(iii) Identifies the existing knowledge gap or unmet research need.
(iv) Clearly presents the rationale for undertaking the study.
(v) States the primary aim, objectives, or research hypothesis of the study.
(vi) Cites relevant and appropriate literature to support the scientific background and rationale.
(vii) Avoids an unnecessarily extensive discussion of well-established knowledge or information that is not directly relevant to the study.
The Introduction should logically lead to the objectives or hypothesis of the study and provide sufficient context for understanding the subsequent sections of the manuscript.
7.2 MATERIALS AND METHODS
The Materials and Methods section should provide sufficient and appropriate detail to enable other researchers to understand, evaluate, and reproduce the study. Authors should describe the materials, experimental procedures, analytical techniques, computational approaches, and statistical methods used in sufficient detail.
Where applicable, authors should report the following:
(i) Materials and reagents used in the study.
(ii) Chemicals, their sources, grades, and suppliers.
(iii) Instruments, equipment, and relevant specifications.
(iv) Experimental procedures and study protocols.
(v) Formulation and preparation methods.
(vi) Analytical and characterization methods.
(vii) Statistical methods and software used for data analysis.
(viii) Computational methods and relevant software or platforms.
(ix) Molecular docking protocols, including relevant parameters, where applicable.
(x) Cell culture conditions and experimental procedures, where applicable.
(xi) Animal experimental procedures, including relevant study details, where applicable.
(xii) Clinical procedures and study protocols, where applicable.
(xiii) Ethical approval details and relevant ethical guidelines, where applicable.
(xiv) Any other methodological information necessary to ensure reproducibility and scientific transparency.
For previously established or published methods, appropriate references should be provided. Any substantial modifications to established methods should be clearly described. Authors should ensure that the reported methodology is sufficiently detailed and accurate to allow independent researchers to reproduce the study.
7.3 RESULTS
The Results section should present the findings of the study in a clear, logical, objective, and scientifically appropriate manner. Results should be organized according to the study objectives and should provide sufficient information to support the conclusions drawn from the research.
Authors should ensure that:
(i) The principal findings of the study are presented clearly and in a logical sequence.
(ii) Results are reported objectively without unnecessary interpretation or discussion.
(iii) Data presented in the text are consistent with the corresponding tables and figures.
(iv) The same information is not unnecessarily repeated in the text, tables, and figures.
(v) Tables and figures are appropriately cited and numbered in the order in which they appear in the manuscript.
(vi) Numerical results are reported with appropriate units and relevant statistical measures.
(vii) Where applicable, measures of variability, statistical significance, confidence intervals, and exact P-values should be reported.
(viii) Results should be sufficiently detailed to allow readers to understand the major findings without ambiguity.
(ix) Only data generated or analyzed as part of the study should be presented, unless clearly identified otherwise.
7.4 DISCUSSION
The Discussion section should provide a clear and critical interpretation of the findings in the context of the study objectives and existing scientific evidence. It should explain the significance of the results and demonstrate how the findings contribute to current knowledge in the relevant field.
Authors should ensure that the Discussion:
(i) Interprets the major findings in relation to the objectives or research hypothesis.
(ii) Compares and contrasts the findings with relevant findings from previously published studies.
(iii) Provides possible scientific, biological, pharmacological, chemical, or mechanistic explanations for the observed findings, where appropriate.
(iv) Highlights the scientific significance, novelty, and potential implications of the findings.
(v) Addresses unexpected, contradictory, or unusual findings and provides possible explanations where appropriate.
(vi) Discusses the strengths and limitations of the study where applicable.
(vii) Clearly distinguishes established evidence from possible interpretations or hypotheses.
(viii) Avoids unsupported claims or conclusions that extend beyond the findings of the study.
(ix) Identifies relevant research gaps or areas requiring further investigation where appropriate.
The Discussion should not simply repeat the information presented in the Results section. Instead, it should critically interpret the findings and explain their relevance in the broader scientific context.
7.5 CONCLUSION
The Conclusion should provide a concise and clear summary of the major findings of the study. It should directly reflect the study objectives and highlight the overall scientific significance and, where applicable, the potential clinical, pharmaceutical, technological, or translational implications of the findings.
Authors should ensure that the Conclusion:
(i) Summarizes the principal findings of the study.
(ii) Clearly addresses the stated objectives or research hypothesis.
(iii) Highlights the scientific significance and novelty of the findings, where appropriate.
(iv) Describes potential practical, clinical, pharmaceutical, or translational implications where supported by the study.
(v) Avoids introducing new data, results, or information that has not been presented and discussed in the manuscript.
(vi) Avoids unsupported or exaggerated claims and should remain consistent with the evidence generated by the study.
8. REVIEW ARTICLES
Review Articles should provide a comprehensive, critical, and balanced evaluation of the available scientific literature rather than serving as a descriptive compilation of previously published information. Authors should synthesize and critically interpret existing evidence, identify important developments and research gaps, and discuss the scientific significance and future implications of the reviewed topic.
Authors should preferably include recent and relevant literature, particularly studies published within the last 5 years, while also citing important landmark studies that have established fundamental concepts in the field.
Where a systematic or structured literature search has been performed, authors should clearly describe the following:
(i) Databases searched.
(ii) Search strategy, including relevant keywords or search terms where appropriate.
(iii) Search period and date of the literature search.
(iv) Inclusion and exclusion criteria.
(v) Study selection and screening process.
(vi) Data extraction and synthesis methods, where applicable.
Systematic Reviews and Meta-analyses should follow appropriate reporting standards and guidelines, such as the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), where applicable. Authors should provide sufficient methodological details to ensure transparency, reproducibility, and scientific rigor of the review process.
9. FIGURES
Figures should be prepared to a high scientific and technical standard and should clearly support the content of the manuscript. Authors are responsible for ensuring that all submitted figures are accurate, legible, appropriately labeled, and relevant to the manuscript.
Authors should ensure that:
(i) Figures are clear, legible, and of sufficient resolution for publication.
(ii) Figures are numbered consecutively according to their first appearance in the manuscript (e.g., Figure 1, Figure 2, Figure 3).
(iii) Each figure is cited in the main text in numerical order.
(iv) Each figure is accompanied by a concise, informative, and self-explanatory figure legend.
(v) All labels, symbols, abbreviations, units, and annotations within figures are clearly readable and consistent with the terminology used in the manuscript.
(vi) Figures should not unnecessarily duplicate information presented in the text or tables.
(vii) Each figure should be submitted in an appropriate electronic format suitable for publication.
(viii) Authors should ensure that all submitted figures are original or that the necessary rights and permissions have been obtained for their use.
(ix) For previously published or adapted figures, appropriate citation and permission from the copyright holder should be provided where required.
(x) Authors should not manipulate or alter images in a manner that could misrepresent or distort the underlying scientific findings.
Example:
Figure 1: Schematic representation of the proposed mechanism of drug delivery.
10. TABLES
Tables should be used to present data and information in a clear, concise, and organized manner. Authors should ensure that each table is directly relevant to the manuscript and does not unnecessarily duplicate information presented in the main text or figures.
Authors should ensure that:
(i) Tables are numbered consecutively according to their first appearance in the manuscript (e.g., Table 1, Table 2, Table 3).
(ii) Each table has a concise, informative, and self-explanatory title.
(iii) All tables are cited in the main text in numerical order.
(iv) Tables are understandable independently of the main text wherever possible.
(v) Data presented in tables are accurate, consistent, and appropriately organized.
(vi) Abbreviations, symbols, statistical values, and other relevant information used in tables are clearly defined in table footnotes or legends where necessary.
(vii) The same data should not be unnecessarily repeated in the text, figures, and tables.
(viii) Tables should preferably be created using the table function in Microsoft Word rather than inserted as images.
(ix) Tables adapted or reproduced from previously published sources should include appropriate citations and permissions where required.
(x) Authors should verify all numerical values, units, statistical information, and references before submission.
Example:
Table 1: Pharmacokinetic characteristics of the selected drug candidates.
11. EQUATIONS AND CHEMICAL STRUCTURES
Mathematical equations and chemical structures should be presented accurately and in a clear, publication-ready format. Authors should ensure that all equations, chemical structures, molecular representations, and related information are scientifically correct and consistent throughout the manuscript.
Authors should ensure that:
(i) Mathematical equations are prepared using appropriate equation-editing software and are presented in an editable format wherever possible.
(ii) Equations are numbered consecutively when they are referred to in the manuscript.
(iii) All variables, symbols, parameters, and units used in mathematical equations are clearly defined.
(iv) Chemical structures are prepared using recognized chemical drawing software, where applicable.
(v) Chemical structures are clearly labeled and presented at an appropriate resolution for publication.
(vi) Chemical names, molecular structures, molecular formulas, stereochemistry, and chemical nomenclature are accurate.
(vii) Chemical structures and molecular representations should be consistent with the chemical names and descriptions provided in the manuscript.
(viii) Previously published or adapted chemical structures should be appropriately cited, and permission should be obtained where required.
12. STATISTICAL ANALYSIS
Where statistical analysis is performed, authors should provide sufficient information to allow readers to understand and evaluate the statistical methods and results. Statistical analyses should be appropriate for the study design, type of data, and research objectives.
Authors should ensure that:
(i) The statistical test or analytical method used is clearly stated.
(ii) The number of independent experiments, biological replicates, technical replicates, participants, or experimental subjects is clearly reported, as applicable.
(iii) The statistical significance threshold or predefined significance level is specified.
(iv) Exact P-values should be reported where appropriate. Where exact P-values are not provided, an appropriate statistical reporting format should be used.
(v) Measures of variability, such as standard deviation (SD), standard error of the mean (SEM), confidence intervals, or other appropriate measures, should be reported.
(vi) The method used to calculate and present the data should be clearly described.
(vii) Statistical software and relevant version information should be reported where appropriate.
(viii) Authors should ensure that the statistical analysis is consistent with the experimental design and adequately supports the conclusions.
(ix) Statements such as “significant,” “statistically significant,” or “non-significant” should be supported by appropriate statistical analysis and clearly defined significance criteria.
(x) Statistical results presented in the text, tables, and figures should be consistent with each other.
13. ETHICAL CONSIDERATIONS
13.1 HUMAN SUBJECTS
Research involving human participants must comply with applicable ethical standards and institutional requirements. Where applicable, authors should provide the following information:
(i) Name of the Ethics Committee or Institutional Review Board (IRB).
(ii) Ethics approval or reference number.
(iii) Date of ethical approval, where applicable.
(iv) A clear statement confirming that informed consent was obtained from participants.
(v) Any additional ethical information required by the relevant institution or regulatory authority.
13.2 ANIMAL STUDIES
Research involving animals must comply with applicable institutional, national, and international ethical requirements for the care and use of laboratory animals. Authors should provide the following information:
(i) Name of the Institutional Animal Ethics Committee or relevant ethics committee.
(ii) Ethics approval or reference number.
(iii) Relevant animal welfare guidelines, regulations, or standards followed.
(iv) Appropriate information regarding animal care and experimental procedures, where necessary.
Manuscripts involving human participants or animals that require ethical approval but do not provide appropriate evidence of ethical oversight may be rejected. Authors may be required to provide documentation of ethical approval during the editorial or peer-review process.
14. INFORMED CONSENT
For manuscripts involving human participants, authors must obtain appropriate informed consent in accordance with applicable ethical requirements. Authors should ensure that participants are adequately informed about the purpose and relevant aspects of the study before providing consent.
Authors should ensure that:
(i) Appropriate informed consent has been obtained from all participants where required.
(ii) For case reports or studies involving identifiable individuals, written informed consent should be obtained where applicable.
(iii) Where photographs, clinical images, case details, medical records, or other potentially identifiable information are included, authors must confirm that appropriate consent has been obtained for publication.
(iv) Personal identifiers and unnecessary identifying information should be removed from the manuscript wherever possible.
(v) The consent statement should be included in the manuscript where applicable.
(vi) Authors should retain documentation of informed consent and provide it to the journal if requested during the editorial or publication process.
15. DATA AVAILABILITY
Authors should provide a Data Availability Statement where applicable. The statement should clearly indicate whether the data generated or analyzed during the study are publicly available, included within the article or supplementary materials, or available from the corresponding author upon reasonable request.
Authors should ensure that:
(i) The Data Availability Statement accurately reflects the accessibility of the data underlying the reported findings.
(ii) Where datasets are publicly available, authors should provide the appropriate repository name, accession number, DOI, or other persistent identifier.
(iii) Where data are available upon reasonable request, the corresponding author should be identified as the contact point for data requests.
(iv) Any restrictions on data availability due to ethical, privacy, confidentiality, intellectual property, or other legitimate considerations should be clearly stated.
(v) If all relevant data are contained within the article and its supplementary information, this should be explicitly stated.
Examples:
“The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.”
or
“All data generated or analyzed during this study are included in the published article and its supplementary information.”
16. ACKNOWLEDGMENTS
The Acknowledgments section may be used to recognize individuals, institutions, or organizations that provided support or assistance during the research or preparation of the manuscript but do not meet the criteria for authorship.
Authors may acknowledge:
(i) Technical assistance.
(ii) Laboratory or experimental assistance.
(iii) Institutional or academic support.
(iv) Administrative or logistical support.
(v) Assistance with data collection, analysis, or other research-related activities, where appropriate.
(vi) Other non-author contributions that supported the research or manuscript preparation.
Authors should obtain permission from individuals or organizations before including their names in the Acknowledgments section, where appropriate.
Individuals who meet the journal's authorship criteria should be included as authors and should not be listed solely in the Acknowledgments section.
17. AUTHOR CONTRIBUTIONS
Current Pharmaceutical Research (CPR) follows the Contributor Roles Taxonomy (CRediT) system for reporting individual author contributions. All authors should have made meaningful contributions to the research and/or manuscript and should approve the final version of the manuscript.
Authors should clearly identify the specific contributions of each author using the following CRediT roles, where applicable:
(i) Conceptualization
(ii) Methodology
(iii) Software
(iv) Validation
(v) Formal Analysis
(vi) Investigation
(vii) Resources
(viii) Data Curation
(ix) Writing – Original Draft
(x) Writing – Review & Editing
(xi) Visualization
(xii) Supervision
(xiii) Project Administration
(xiv) Funding Acquisition
Authors should use only those CRediT roles that accurately reflect their individual contributions. Not every author is required to have a contribution in every category.
Example:
Author Contributions: AB: Conceptualization, Methodology, Investigation, Writing – Original Draft; CD: Formal Analysis, Data Curation, Visualization, Writing – Review & Editing; EF: Supervision, Project Administration.
The corresponding author is responsible for ensuring that the contribution statement accurately represents the contributions of all authors.
18. FUNDING
Authors must disclose all sources of financial support received for the research, manuscript preparation, or publication. Funding information should be provided clearly and accurately, including the name of the funding agency, grant number, where applicable, and any other relevant funding details.
Authors should ensure that:
(i) All sources of financial support related to the study are disclosed.
(ii) Grant numbers or project identification numbers should be provided where applicable.
(iii) Each funding source should be appropriately acknowledged.
(iv) If the research received no external financial support, this should be clearly stated.
(v) Funding disclosure should be consistent with the information provided in any relevant institutional or grant documentation.
Example:
Funding: This research received no external funding.
Or, where applicable:
Funding: This work was supported by [Name of Funding Agency] under Grant No. [XXXX].
19. CONFLICT OF INTEREST
All authors must disclose any financial or non-financial interests that could reasonably be perceived as influencing the research, interpretation of results, or preparation of the manuscript. Authors should provide a clear and transparent statement regarding any potential conflicts of interest.
Authors should ensure that:
(i) All relevant financial conflicts of interest are disclosed.
(ii) Any relevant non-financial, professional, personal, academic, or institutional conflicts of interest are disclosed.
(iii) Each author has reviewed and approved the conflict of interest statement before submission.
(iv) Any relationships with organizations, institutions, companies, funding bodies, or other entities that may have an interest in the submitted work are appropriately disclosed.
(v) If no conflict of interest exists, the following statement should be included:
Conflict of Interest: The authors declare that they have no conflict of interest.
20. ARTIFICIAL INTELLIGENCE AND LARGE LANGUAGE MODELS
Authors must disclose the use of generative artificial intelligence (AI) tools or large language models (LLMs) when such tools have been used in the preparation, editing, analysis, or other aspects of the manuscript.
Authors should ensure that:
(i) The use of generative AI or LLM-based tools is transparently disclosed in the manuscript.
(ii) AI tools or large language models must not be listed as authors or co-authors.
(iii) Authors remain fully responsible for the accuracy, originality, integrity, and scientific validity of the submitted manuscript.
(iv) Any content generated or modified using AI tools must be critically reviewed, verified, and appropriately edited by the authors.
(v) Authors should not rely on AI-generated content without independent scientific verification.
(vi) The use of AI for fabricating or generating scientific data, manipulating results, fabricating or altering references, or creating misleading scientific content is not acceptable.
(vii) Authors should disclose the name of the AI tool and its specific purpose where applicable.
Example:
AI Declaration: The authors used [name of tool] for language improvement and/or grammatical editing. All generated or modified content was critically reviewed and verified by the authors, who remain fully responsible for the accuracy and integrity of the manuscript.
21. REFERENCES
References should be relevant, accurate, and directly support the information presented in the manuscript. Current Pharmaceutical Research (CPR) follows a numbered reference style in which references are cited in the text using square brackets, such as [1], [2], [3], and listed in numerical order according to their first appearance in the manuscript.
Authors should ensure that:
(i) References are numbered consecutively according to their first appearance in the text.
(ii) Each reference citation is enclosed in square brackets, for example, [1], [2], [3–5].
(iii) Multiple references should be cited together where appropriate, for example, [1,3,5] or [2–6].
(iv) The reference list should follow the same numerical order as the citations in the manuscript.
(v) All references cited in the text must appear in the reference list, and all references in the reference list must be cited in the manuscript.
(vi) Author names should be accurately reported.
(vii) Article titles should be provided accurately.
(viii) Journal titles should be written consistently according to the journal's prescribed reference style.
(ix) The publication year, volume, issue, page numbers, or article number should be provided where applicable.
(x) DOI should be included wherever available.
(xi) Authors should verify the accuracy and completeness of all bibliographic information before submission.
(xii) Excessive self-citation should be avoided.
(xiii) Citation manipulation, including unnecessary citation of articles, journals, or authors to influence citation metrics, is not permitted.
(xiv) The prescribed reference style should be applied consistently throughout the manuscript.
EXAMPLES OF REFERENCE FORMATTING
Journal Article:
[1] Author AA, Author BB. Title of the article. Journal Name. 2025;20(3):125–135. doi:10.xxxx/xxxxx.
Journal Article with Article Number:
[2] Author AA, Author BB, Author CC. Title of the article. Journal Name. 2026;12:100125. doi:10.xxxx/xxxxx.
Book:
[3] Author AA. Title of the Book. 3rd ed. Publisher; 2025.
Book Chapter:
[4] Author AA, Author BB. Title of the chapter. In: Editor AA, Editor BB, editors. Title of the Book. Publisher; 2025. p. 25–40.
Website:
[5] Organization/Author. Title of webpage. Website Name. Year. Available from: URL. Accessed [date].
The journal recommends that authors carefully check every reference for accuracy before submission, particularly the author names, article title, journal name, publication year, volume, issue, page range or article number, and DOI.
22. PLAGIARISM AND SIMILARITY
All submitted manuscripts may be screened for plagiarism, inappropriate text overlap, duplicate publication, and other forms of academic misconduct using appropriate similarity-detection tools. Authors are responsible for ensuring the originality and integrity of their submitted work.
Authors should ensure that:
(i) The submitted manuscript is original and has not been plagiarized from previously published or unpublished sources.
(ii) All sources and previously published information are appropriately acknowledged and cited.
(iii) Text, data, ideas, figures, tables, images, or other material reproduced or adapted from previously published sources are properly cited and used with appropriate permission where required.
(iv) Self-plagiarism and substantial duplication of previously published content are avoided.
(v) The manuscript is not simultaneously submitted to another journal.
(vi) Authors should carefully review the manuscript for inappropriate text overlap before submission.
(vii) The overall similarity index should preferably be within 10–15%, excluding references, commonly used technical terms, standard phrases, and other appropriately excluded material.
(viii) A similarity score within the recommended range does not by itself guarantee acceptance; the editorial team may assess the nature, location, and source of the identified overlap.
(ix) Manuscripts containing substantial plagiarism, intentional text duplication, fabricated content, or other forms of unethical publication practice may be rejected.
Authors remain responsible for the originality, integrity, and ethical compliance of the submitted manuscript.
23. DUPLICATE SUBMISSION AND PUBLICATION
Authors must ensure that manuscripts submitted to Current Pharmaceutical Research (CPR) are original and are not simultaneously under consideration by another journal. The same manuscript, in whole or in substantial part, must not be submitted to more than one journal at the same time.
Authors should ensure that:
(i) The manuscript is not under active consideration by another journal at the time of submission to CPR.
(ii) Manuscripts that have been published previously in whole or in substantial part should not be submitted as original work.
(iii) Previously published data, text, figures, tables, or other material must be appropriately disclosed and cited.
(iv) Substantial overlap with previously published or simultaneously submitted manuscripts should be clearly disclosed to the editorial office.
(v) Duplicate or redundant publication, including substantial republication of the same findings without appropriate disclosure, is not permitted.
(vi) If a manuscript is withdrawn from another journal, authors should ensure that the withdrawal has been formally completed before submitting it to CPR.
(vii) Authors must inform the editorial office of any related manuscripts that have been published, accepted, or are currently under consideration elsewhere.
(viii) Manuscripts that violate the journal's policy on duplicate submission or publication may be rejected, and appropriate editorial action may be taken where necessary.
24. AUTHORSHIP
Authorship should be based on substantial and meaningful contributions to the research and/or manuscript. All individuals listed as authors should meet the journal's authorship criteria and should be able to take responsibility for their respective contributions.
All listed authors should:
(i) Have made a meaningful contribution to the conception, design, conduct, analysis, interpretation, or other substantive aspects of the study.
(ii) Participate in drafting the manuscript or critically revising it for important intellectual content.
(iii) Review and approve the final version of the manuscript before submission and publication.
(iv) Agree to be accountable for their contributions and accept responsibility for the integrity of the work.
(v) Ensure that any questions related to the accuracy or integrity of their contribution are appropriately addressed.
Individuals who have not made substantial contributions to the work should not be listed as authors. Honorary, guest, or gift authorship is not permitted.
Changes to authorship after manuscript submission, including addition, removal, or change in the order of authors, should be supported by written consent from all authors and may require approval from the editorial office. The corresponding author is responsible for communicating any proposed authorship changes to the journal.
25. COPYRIGHT AND LICENSING
j*Current Pharmaceutical Research (CPR)* is an open-access journal committed to providing broad and unrestricted access to published scholarly research. Copyright and licensing terms are clearly stated for all published articles to ensure transparency regarding the rights of authors, readers, and other users.
Authors should ensure that:
(i) The applicable Creative Commons license for the published article is clearly stated on the journal website and in the published article.
(ii) CPR may publish articles under a Creative Commons license, such as the Creative Commons Attribution (CC BY) license, as specified in the journal's publishing agreement.
(iii) The applicable license determines how the published work may be accessed, reused, shared, and adapted by others.
(iv) Authors retain the rights provided to them under the applicable publishing agreement and license.
(v) Authors are responsible for ensuring that all third-party material included in the manuscript has the necessary permissions or is appropriately licensed for publication.
(vi) Any restrictions or specific conditions associated with third-party material should be clearly identified.
(vii) The copyright and licensing information should remain consistent between the journal website, publishing agreement, and final published article.
26. OPEN ACCESS POLICY
Current Pharmaceutical Research (CPR) follows an open-access publishing model to promote the broad and unrestricted dissemination of scientific research. All accepted articles are made freely available to readers upon publication, subject to the applicable copyright and licensing terms.
The journal's open-access policy includes the following:
(i) All accepted and published articles are made freely accessible to readers without subscription or paywall restrictions.
(ii) Readers may access, read, download, share, and reuse published articles in accordance with the applicable Creative Commons license and the journal's copyright policy.
(iii) The specific Creative Commons license applicable to each article is clearly stated on the journal website and in the published article.
(iv) The applicable license defines the rights and conditions governing the sharing, reproduction, distribution, and adaptation of published content.
(v) Appropriate attribution to the original authors and source should be provided when published material is reused in accordance with the applicable license.
(vi) Any restrictions applicable to third-party material included within an article should be clearly identified.
(vii) The journal's copyright and licensing information should remain clearly accessible to authors and readers throughout the publication process.
27. ARTICLE PROCESSING CHARGES
Current Pharmaceutical Research (CPR) follows a transparent Article Processing Charge (APC) policy. Any applicable publication charges are clearly disclosed to authors before manuscript submission and acceptance. The journal does not impose any hidden or undisclosed charges.
The applicable Article Processing Charges are as follows:
(i) Indian Authors: INR ₹7,000 per accepted article.
(ii) Foreign Authors: USD $99 per accepted article.
The APC is applicable only to manuscripts that are accepted for publication. Submission of a manuscript does not guarantee acceptance, and payment of the APC does not influence the editorial or peer-review decision.
Authors should note that the applicable APC covers the publication and editorial processing of the accepted manuscript. Any additional charges, if applicable, will be communicated to the authors in advance.
28. PEER REVIEW
Current Pharmaceutical Research (CPR) follows a rigorous peer-review process to ensure the scientific quality, originality, relevance, and integrity of published manuscripts. All submitted manuscripts are initially evaluated by the editorial team before being considered for external peer review.
The peer-review process includes the following stages:
(i) Initial Editorial Assessment: Each submitted manuscript is assessed for its suitability within the scope of the journal, scientific quality, originality, ethical compliance, completeness, and overall language and presentation.
(ii) Editorial Screening: Manuscripts that do not meet the journal's scope, minimum scientific standards, ethical requirements, or submission criteria may be declined without external peer review.
(iii) Peer Review: Manuscripts considered suitable for further evaluation may be sent to independent reviewers with relevant expertise in the subject area. Reviewers evaluate the scientific quality, methodology, originality, interpretation of results, presentation, and overall significance of the manuscript.
(iv) Editorial Decision: The Editor-in-Chief or designated Handling Editor makes the final editorial decision after considering the reviewers' comments, recommendations, and the overall scientific assessment of the manuscript.
(v) Revision: Where revisions are requested, authors should address the reviewers' comments carefully and provide a clear response to each point. A revised manuscript may be returned to the original reviewers for further evaluation where appropriate.
Possible editorial decisions include:
(i) Accept
(ii) Minor Revision
(iii) Major Revision
(iv) Reject
The final decision regarding publication rests with the Editor-in-Chief or designated Handling Editor. Peer-review recommendations are considered carefully but do not automatically determine the final editorial decision.
29. CORRECTIONS AND RETRACTIONS
Current Pharmaceutical Research (CPR) is committed to maintaining the accuracy, transparency, and integrity of the published scientific record. The journal may publish corrections, expressions of concern, or retractions when significant errors, ethical issues, research misconduct, or other concerns affecting the reliability or integrity of a published article are identified.
The journal may take the following actions where appropriate:
(i) Correction: Minor or significant errors that do not invalidate the overall findings of an article may be corrected through a formal correction notice.
(ii) Expression of Concern: An expression of concern may be issued when substantial questions regarding the reliability, integrity, or ethical aspects of a published article arise but the available evidence is insufficient to make an immediate final determination.
(iii) Retraction: An article may be retracted when serious errors, unreliable findings, plagiarism, fabrication, falsification, duplicate publication, ethical violations, or other forms of misconduct substantially compromise the validity or integrity of the published work.
(iv) Retraction notices will clearly identify the affected article and provide the reason for the retraction, where appropriate.
(v) The original published record will be maintained where possible, with an appropriate notice clearly indicating the correction, expression of concern, or retraction.
Authors are expected to cooperate fully with the editorial office in investigating and resolving post-publication concerns. The journal may request supporting data, documentation, ethical approvals, or other relevant information when necessary to assess the integrity of a published article.
30. RESEARCH INTEGRITY
Current Pharmaceutical Research (CPR) is committed to maintaining high standards of research integrity, publication ethics, transparency, reproducibility, responsible authorship, and ethical research conduct. Authors, reviewers, and editors are expected to uphold these principles throughout the submission, peer-review, and publication process.
The journal considers the following practices to be serious concerns:
(i) Fabrication or falsification of research data, results, images, or other scientific information.
(ii) Plagiarism, including substantial unattributed use of previously published text, ideas, data, or other material.
(iii) Duplicate or redundant publication.
(iv) Simultaneous submission of the same manuscript to multiple journals.
(v) Manipulation or inappropriate interference with the peer-review process.
(vi) Fabrication, manipulation, or inappropriate use of reviewer identities or recommendations.
(vii) Inappropriate, honorary, guest, or gift authorship, as well as unjustified exclusion of contributors who meet authorship criteria.
(viii) Undisclosed conflicts of interest that may affect the integrity or interpretation of the work.
(ix) Failure to obtain required ethical approval or informed consent.
(x) Manipulation, fabrication, or inappropriate presentation of scientific images or data.
(xi) Citation manipulation or other practices intended to improperly influence citation or publication metrics.
(xii) Any other form of research or publication misconduct that may compromise the integrity of the scientific record.
Suspected research or publication misconduct may be investigated by the editorial office. Where necessary, the journal may request relevant data, documentation, ethical approvals, authorship information, or other supporting materials from the authors or their institutions.
Appropriate editorial action may be taken based on the outcome of an investigation, including manuscript rejection, correction, expression of concern, or retraction of a published article. Authors are expected to cooperate fully with the journal during any investigation and to provide accurate and complete information when requested.
31. SUBMISSION CHECKLIST
Before submitting a manuscript to Current Pharmaceutical Research (CPR), authors should carefully review the following requirements and ensure that all applicable criteria have been fulfilled:
(i) The manuscript falls within the scope of Current Pharmaceutical Research.
(ii) The manuscript is original and is not simultaneously under consideration by another journal.
(iii) All authors have reviewed and approved the final version of the manuscript.
(iv) The names, order, affiliations, and institutional details of all authors are accurate.
(v) A corresponding author has been clearly identified, and complete contact information has been provided.
(vi) The manuscript includes an appropriate title, abstract, and 4–6 keywords.
(vii) The manuscript follows the journal's prescribed formatting and structural requirements.
(viii) All figures and tables are appropriately numbered, titled, and cited in the main text.
(ix) Figures are of sufficient quality and appropriate permissions have been obtained for copyrighted or previously published material, where required.
(x) Ethical approval and relevant ethical statements are provided for studies involving human participants or animals, where applicable.
(xi) Informed consent has been obtained and appropriately reported, where applicable.
(xii) Funding information is provided.
(xiii) A Conflict of Interest statement is included.
(xiv) An Author Contributions statement using the CRediT taxonomy is included.
(xv) A Data Availability Statement is included, where applicable.
(xvi) An AI/LLM Declaration is included, where applicable.
(xvii) References are complete, accurate, numbered consecutively, and consistently formatted according to the CPR reference style.
(xviii) In-text citations and the reference list are cross-checked for consistency.
(xix) Appropriate permissions have been obtained for copyrighted text, figures, tables, images, or other third-party material, where required.
(xx) The manuscript has been checked for plagiarism and inappropriate text overlap and meets the journal's similarity requirements.
(xxi) The manuscript has been carefully checked for English language, grammar, spelling, formatting, and overall presentation.
(xxii) All information provided during submission is complete, accurate, and consistent with the submitted manuscript.
32. EDITORIAL CONTACT
Current Pharmaceutical Research (CPR)
Published by Sprout Publication
ISSN: 3049-2955
For manuscript submissions, editorial queries, peer-review correspondence, publication-related matters, or other journal-related communications, authors should contact the editorial office through the official contact details provided on the journal website.
Authors are requested to include the manuscript title and manuscript identification number, where applicable, in all correspondence with the editorial office to facilitate efficient processing of their queries.
```
